Contracts › 75A50125F61012
75A50125F61012: To Conduct a Clinical Trial to Assess the Safety, Immunogenicity, Antigen Dose, of Matrix-M Adjuvant in Combination With U.S. Domestically Manufactured, Egg-Based A/Astrakhan/3212/2020 (H5N8) Influenza Virus Vaccine in Healthy Adults and Older Adults
Awarded to Sanofi Vaccines Us Inc. by Office of Assistant Secretary for Preparedness and Response.
$24.9Mobligated
$24.9Mpotential value
04 September 2028current end date
See modifications, all subcontractors and funding in FedSift →
| Contract | 75A50125F61012 |
|---|---|
| Vehicle | 75A50122D00003 |
| Awardee | Sanofi Vaccines Us Inc. |
| Awarding agency | Office of Assistant Secretary for Preparedness and Response |
| Awarding office | BARDA - ASPR / DAAPPO / BARDA DCMA |
| NAICS | 541714 Research and Development in Biotechnology (Except Nanobiotechnology) |
| PSC | AN12 Health R&D Services; Health Care Services; Applied Research |
| Place of performance | PA |
| Period of performance | 05 September 2025 to 04 September 2028 |
| Potential end | 04 September 2028 |
| Estimated recompete solicitation | ~Q1 2028 (estimate, ~6 months before expiry) |
Source: USASpending.gov (FPDS), public federal procurement data, as the agency reported it. Our record updated 03 October 2026. The solicitation date is an estimate from the end date, not a posted date.
Other expiring 541714 contracts · All expiring contracts · USASpending record